Pattern of Retinopathy: Although the locus of toxic damage is parafoveal in many eyes, Asian patients often show an extramacular pattern of damage. Dose: We recommend a maximum daily HCQ use of 5.0 mg/kg real weight, which correlates better with risk than ideal weight. Chloroquine base meaning Long term effects of plaquenil Chloroquine retrovirus production Plaquenil toxicity macula oct Abstract. Background The American Academy of Ophthalmology recommendations on screening for chloroquine CQ and hydroxychloroquine HCQ retinopathy are revised in light of new information about the prevalence of toxicity, risk factors, fundus distribution, and effectiveness of screening tools. Plaquenil hydroxycholoroquine is a medication used to treat lupus, rheumatoid arthritis and other inflammatory and dermatologic conditions. It is very effective and the risk of damage to the eye is very low the first five years if the patient is receiving the recommended dose and does not have special risk factors like kidney damage. DMARD MONITORING GUIDELINES – FOR GP INFORMATION Hydroxychloroquine A. Indications Licensed RA, connective tissue diseases systemic and discoid lupus and some photosensitive dermatological conditions B. Dose Grade of evidence C Typical regime 200–400 mg daily. Dosage may be reduced to 200 mg daily depending on clinical response. Risk of Toxicity: The risk of toxicity is dependent on daily dose and duration of use. There are no similar demographic data for CQ, but dose comparisons in older literature suggest using 2.3 mg/kg real weight. Monitoring hydroxychloroquine RCOphth guideline Hydroxychloroquine and Chloroquine., PLAQUENIL MONITORING — Ocean Opthalmology Plaquenil and total knee replacement Monitoring tests, but that monitoring begins after one year of therapy for all patients on chloroquine. Monitoring may be best incorporated into the hospital eye service via virtual clinics. The results of monitoring should be communicated back to the prescribing doctor, patient and GP as normal, possible or definite hydroxychloroquine retinopathy. Hydroxychloroquine and Chloroquine Retinopathy.. Hydroxychloroquine gp guidelines 2008. Monitoring and Preventing Hydroxychloroquine, Plaquenil.. Many systemic medications may cause retinal toxicity. One such commonly used medication for dermatologic and rheumatologic inflammatory conditions is hydroxychloroquine Plaquenil, a chloroquine derivative. It is used to treat many diseases including malaria, rheumatoid arthritis and systemic lupus erythematosus. Hydroxychloroquine is a disease-modifying anti-rheumatic drug DMARD. It regulates the activity of the immune system, which may be overactive in some conditions. Hydroxychloroquine can modify the underlying disease process, rather than simply treating the symptoms. Since the initial screening and monitoring recommendations were published in 2002, there have been reports of retinal toxicity associated with the use of Plaquenil. Furthermore, the advent of novice sensitive diagnostic modalities has led to a revision of the recommended guidelines for patients using Plaquenil see “2011 Plaquenil Screening.